{"id":"nivolumab-and-recombinant-human-hyaluronidase","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Immune-related adverse events (irAEs)"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Rash"},{"rate":null,"effect":"Pneumonitis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Nivolumab is a PD-1 checkpoint inhibitor that restores T-cell mediated anti-tumor immunity by blocking the PD-1/PD-L1 interaction. The addition of recombinant human hyaluronidase (rHuPH20) degrades hyaluronic acid in the tumor microenvironment, reducing physical barriers and enhancing intratumoral penetration and distribution of nivolumab, potentially improving efficacy.","oneSentence":"Nivolumab blocks PD-1 to enhance anti-tumor immunity, while recombinant human hyaluronidase improves drug penetration into tumors by degrading hyaluronic acid in the extracellular matrix.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:23:10.173Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced or metastatic solid tumors (investigational combination in phase 3 trials)"}]},"trialDetails":[{"nctId":"NCT04759586","phase":"PHASE3","title":"Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-10-05","conditions":"Primary Mediastinal Large B-Cell Lymphoma","enrollment":244},{"nctId":"NCT07383441","phase":"PHASE3","title":"Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer","status":"NOT_YET_RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2026-06-10","conditions":"Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8","enrollment":718},{"nctId":"NCT06697197","phase":"PHASE1, PHASE2","title":"A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2025-02-17","conditions":"Advanced Solid Tumors","enrollment":413},{"nctId":"NCT03656718","phase":"PHASE1, PHASE2","title":"A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2018-10-29","conditions":"Neoplasms by Site","enrollment":139},{"nctId":"NCT04810078","phase":"PHASE3","title":"A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2021-05-21","conditions":"Clear Cell Renal Cell Carcinoma","enrollment":681},{"nctId":"NCT03446040","phase":"PHASE1, PHASE2","title":"An Investigational Immunotherapy Study of BMS-986258 Alone and in Combination With Nivolumab in Participants With Solid Cancers That Are Advanced or Have Spread","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2018-03-08","conditions":"Advanced Cancer","enrollment":92},{"nctId":"NCT05625399","phase":"PHASE3","title":"A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2023-03-06","conditions":"Melanoma","enrollment":579},{"nctId":"NCT06101134","phase":"PHASE2","title":"A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2023-11-06","conditions":"Melanoma","enrollment":100},{"nctId":"NCT05297565","phase":"PHASE3","title":"A Study to Compare Nivolumab Administered Subcutaneously vs Intravenous in Melanoma Participants Following Complete Resection","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2022-08-02","conditions":"Melanoma","enrollment":14},{"nctId":"NCT05496192","phase":"PHASE2","title":"A Study of Nivolumab Intravenous (IV) to Subcutaneous (SC) Switch in Adjuvant Melanoma and Bladder Cancer","status":"WITHDRAWN","sponsor":"Bristol-Myers Squibb","startDate":"2023-05-31","conditions":"Melanoma, Urothelial Carcinoma","enrollment":""},{"nctId":"NCT04112498","phase":"PHASE1","title":"A Phase 1, Bioavailability Study of Relatlimab in Combination With Nivolumab","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2019-10-01","conditions":"Cancer","enrollment":24},{"nctId":"NCT02754141","phase":"PHASE1, PHASE2","title":"An Investigational Immuno-therapy Study of Experimental Medication BMS-986179 Given Alone and in Combination With Nivolumab","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2016-06-21","conditions":"Malignant Solid Tumor","enrollment":235},{"nctId":"NCT04311710","phase":"PHASE1","title":"A Study Evaluating the Drug Levels of Iplimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor Types","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2020-06-25","conditions":"Tumor","enrollment":21}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Hyaluronidase-nvhy and Nivolumab","Hyaluronidase/Nivolumab","Nivolumab and Hyaluronidase-nvhy","Nivolumab and rHuPH20","Nivolumab/Recombinant Human Hyaluronidase"],"phase":"phase_3","status":"active","brandName":"Nivolumab and Recombinant Human Hyaluronidase","genericName":"Nivolumab and Recombinant Human Hyaluronidase","companyName":"SWOG Cancer Research Network","companyId":"swog-cancer-research-network","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Nivolumab blocks PD-1 to enhance anti-tumor immunity, while recombinant human hyaluronidase improves drug penetration into tumors by degrading hyaluronic acid in the extracellular matrix. Used for Advanced or metastatic solid tumors (investigational combination in phase 3 trials).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}